All In Biotech

Free tool

FAERS Monitor: Ellence

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050778 or its brand name (Ellence, Epirubicin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

6,498

Serious

6,286

97% of reports

Hospitalization

2,517

Death reported

478

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myelosuppression726
  • nausea553
  • white blood cell count decreased493
  • alopecia459
  • vomiting419
  • febrile neutropenia371
  • pyrexia339
  • asthenia326
  • neutropenia278
  • hepatic function abnormal274
  • neutrophil count decreased272
  • off label use235
  • diarrhoea221
  • decreased appetite192
  • fatigue188

Reports by year received

View as table
YearReports
200433
200514
200620
200762
200867
200950
2010137
2011269
2012334
2013135
2014120
2015185
2016169
2017153
2018361
2019337
2020290
2021388
2022709
2023722
2024838
2025636
2026469

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,661 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal72666.662.145,955
hepatic function abnormalSignal27423.921.35,965
neutrophil count decreasedSignal27221.719.35,336
febrile neutropeniaSignal37118.216.55,998
white blood cell count decreasedSignal49314.813.66,326
alopeciaSignal4597.66.92,634
neutropeniaSignal2786.65.91,329
pyrexiaSignal3393.22.9510
vomitingSignal4192.92.6526
astheniaSignal3262.82.5384
decreased appetiteSignal1922.72.3202
nauseaSignal5532.32.1403
diarrhoea2211.11.02
off label use2350.90.85
fatigue1880.80.712

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.